spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Porton Biopharma opens new facility to make more of its childhood cancer cure


In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.



The state-of-the-art facility has been designed and built around a new 3000 litre fermenter which is a significant increase over existing capacity and will enable PBL to increase the amount of product it will be able to manufacture in the future.

The new multi-million pound building has a footprint of approximately 2100m2. This includes the main fermentation hall, down-stream processing rooms for harvesting product, plus all the associated services of purified water, steam, air and effluent treatment that are required in a modern pharmaceutical facility that meets the latest regulatory standards. These systems have been designed to interact seamlessly and are operated by the latest process-control system. This will enable PBL’s production technicians to easily view and control any of the component parts via a series of hi-tech interactive screens.



Mike Raine Director of Engineering for PBL said “Today represents an important milestone where we can see the physical results of all the hard work in the design, planning and build that have gone into this project. We are now looking forward to the next challenge of qualifying and validating the equipment to ensure that everything is working as specified, before going into full production sometime over the next year.”

Commenting on the ceremony John Glen said, “I was delighted to be welcomed back to open this new facility after having performed the ground-breaking ceremony in May 2016, the transformation of the site is astounding. Having this facility in Wiltshire is also a superb local example of the government’s industrial strategy, which specifically includes supporting the life-sciences sector and building prosperous communities – a good news event for Salisbury!”.

Dr Roger Hinton MD of PBL said “We are looking forward to the day when this facility comes on-line because that, along with the other investments that we have made, means that we will be able to meet the growing global demand for our product. This helps to grow the value of Porton Biopharma Limited, but most importantly it means that we will be able to save the lives of more children who suffer from this form of leukaemia in future.”
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT Acquires UK-based Clinical Trials Laboratory Services

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
More info >>


White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement